Tidmarsh, who has founded and served as CEO of several biotech companies, will lead a crucial FDA division that reviews the majority of new drug applications.
Related Posts
New tariffs could raise home prices and sideline potential buyers
Home prices are already at records, and tariffs on building materials from Canada and Mexico could add even more pressure to the market.
Merck says experimental RSV treatment protected infants in trial, paving way for potential approval
Merck is discussing the study data with regulators worldwide, with a goal of making the treatment available for infants as early as the 2025 to […]
Palantir is a buy that has further to run, and other takes on AI plays
Mainstay Capital Management’s David Kudla joined CNBC’s ‘Power Lunch’ to discuss his views on three stocks.